CytomX (CTMX) Q2 Revenue Drops 26%
CytomX Therapeutics (NASDAQ:CTMX), a biotechnology company focused on developing targeted oncology therapies, reported its second quarter 2025 results on August 7, 2025. In the period, the most significant developments included a year-over-year decline in GAAP revenue, improvements in cost discipline, and notable progress in the clinical pipeline, especially for its lead candidate, CX-2051. Reported GAAP revenue of $18.658 million narrowly missed analyst expectations of $18.767 million, while Diluted earnings per share (GAAP) were $(0.00), better than the estimated $(0.06) and last year's $(0.08). While the top-line GAAP revenue was weaker than expected, cost controls, reduced operating expenses, and a successful $100 million equity raise significantly improved the company’s financial position.
Source: Analyst estimates for the quarter provided by FactSet.
CytomX Therapeutics is a clinical-stage biotechnology firm aiming to develop oncology therapies that are selectively activated in tumors to minimize side effects. The company’s core technology, called the PROBODY platform, uses conditionally activated biologics to direct antibody-based therapies to cancer cells while reducing their action in normal tissues.
Source Fool.com
